This study found that:
- In rats, co-administration with nalfurafine reduced the dose of oxycodone required to lower pain responses in models of human chronic pain.
- The combination treatment generated less abuse liability and produced less respiratory depression than oxycodone alone.
Spurred by the epidemic of opioid overdoses and deaths in the United States, researchers are seeking new formulations of opioid pain relievers that will reduce the medications’ potential for misuse and overdose without compromising their analgesic effectiveness. In one such effort, NIDA-funded researchers recently tested a combination of the prescription analgesic oxycodone and nalfurafine, which is used in Japan to treat itching associated with hemodialysis and chronic liver disease.
The two medications act on different opioid receptors in the brain. Oxycodone and most other prescription opioid analgesics stimulate mu opioid receptors, suppressing pain but also causing rewarding effects that confer risk for misuse and addiction. Mu receptor agonists also suppress breathing, making overdoses potentially fatal.
In contrast, nalfurafine stimulates kappa opioid receptors. Kappa receptor agonists can reduce the rewarding effects of mu agonists without altering their ability to relieve pain. They are also less likely than mu agonists to depress the respiratory system. However, they carry other side effects, including creating feelings of uneasiness and sadness (dysphoria) and even psychosis.
In the new study, Drs. E. Andrew Townsend and Kevin Freeman from the University of Mississippi Medical Center in Jackson, along with colleagues from several institutions, administered various combinations of oxycodone/nalfurafine to rats to determine if they might enhance oxycodone’s positive effects and reduce its negative effects. They examined three key endpoints:
- Self-administration of oxycodone (a measure of abuse potential)
- Pain relief in response to heat
- Respiratory depression.
Text Description of Graphic
The analyses showed that combining oxycodone with nalfurafine at a ratio of 18:1 greatly reduced the dose of oxycodone required to relieve pain (see Figure 1). Rats did not self-administer significantly more of the combination than they did saline, suggesting that it did not produce the rewarding sensations that can lead to abuse and addiction. The researchers also observed no signs of respiratory depression from the combination at this ratio (see Figure 2). Higher oxycodone/nalfurafine ratios also enhanced oxycodone’s pain-killing effects, but showed evidence of abuse potential and/or respiratory depression.
These findings suggest that combined mu/kappa opioid receptor agonist medications may be able to save lives by relieving pain while limiting potentially fatal side effects. When asked about the anticipated benefits of this work, Dr. Townsend asserts, “The majority of illicit opioid users begin their path to addiction by misusing prescription opioid medications. We feel that if more steps are taken to reduce the recreational appeal of these medications, fewer people will progress from pain management to opioid use disorder.” Future studies will need to examine whether oxycodone/nalfurafine combinations have similar effects in humans.
Text Description of Graphic
The study was supported by NIH grant DA039167.
Townsend, E.A., Naylor, J.E., Negus, S.S., et al. Effects of nalfurafine on the reinforcing, thermal antinociceptive, and respiratory-depressant effects of oxycodone: Modeling an abuse-deterrent opioid analgesic in rats. Psychopharmacol 234(17):2597–2605, 2017.
Drugs of Abuse
Get this Publication
Cite this article
NIDA. (2018, June 19). In Animals, Opioid Combination Shows Promise for Safer Pain Relief . Retrieved from https://www.drugabuse.gov/news-events/nida-notes/2018/06/in-animals-opioid-combination-shows-promise-safer-pain-relief